Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Cell Immunol. 2018 Oct 13;334:87–98. doi: 10.1016/j.cellimm.2018.10.003

Table 2:

Summary of Combination Trials with Checkpoint Inhibitors. (ORR: overall response rate, sCR: stringent complete response, CR: complete response, irAEs: Immune related adverse events, NR: not reported).

Combination N ORR (%) Best Response i irAEs(%) Grade 3–4 irAEs Ref(s)
Pembrolizumab, Pomalidome, Dexamethasone 48 60 CR 33 10 116
Pembrolizumab, Lenalidomide, Dexamethasone 62 44 sCR 13 0 117
Pembrolizumab, Pomalidome, Dexamethasone 125 34 CR 58 18 118,119
Pembrolizumab, Lenalidomide, Dexamethasone 151 64 NR 68 44 119,120